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Abstract
Interferon- α2 reduces elevated blood cell counts and splenomegaly in patients with 
myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its 
use is limited by inflammation- mediated toxicity, leading to treatment discontinuation 
in 10- 30% of patients. Ruxolitinib, a potent anti- inflammatory agent, has demonstrated 
benefit in myelofibrosis (MF) and polycythemia vera (PV) patients. Combination ther-
apy (CT) with these two agents may be more efficacious than monotherapy with either, 
potentially improving tolerability of interferon- α2 as well. We report the preliminary 
results from a phase II study of CT with pegylated interferon- α2 and ruxolitinib in 50 
MPN patients (PV, n = 32; low- /intermediate- 1- risk MF, n = 18), the majority (n = 47) 
being resistant and/or intolerant to interferon- α2 monotherapy. Objectives included 
remission (2013 revised criteria encompassing histologic, hematologic, and clinical 
responses), complete hematologic response (CHR), molecular response, and toxicity. 
Follow- up was 12 months. Partial remission (PR) and sustained CHR were achieved in 
9% and 44% of PV patients, respectively. In MF patients, complete or partial remission 
was achieved in 39%, and sustained CHR in 58%. The median JAK2V617F allele bur-
den declined significantly in both groups. Hematologic toxicity was the most common 
adverse event and was managed by dose reduction. Thirty- seven serious adverse events 
were recorded in 23 patients; the discontinuation rate was 20%. We conclude that CT 
with interferon- α2 and ruxolitinib is efficacious in patients with low- /intermediate- 1- 
risk MF and, to a lesser extent, in patients with PV. These preliminary results encourage 
phase III studies as well as a study with CT in newly diagnosed MPN patients. 
K E Y W O R D S
combination therapy, interferon-alpha, myeloproliferative neoplasms, polycythemia vera, primary 
myelofibrosis, ruxolitinib
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1 |  INTRODUCTION
The Philadelphia chromosome- negative chronic myeloprolif-
erative neoplasms (MPN) - essential thrombocythemia (ET), 
polycythemia vera (PV) and primary myelofibrosis (PMF) 
- are acquired hematopoietic stem cell neoplasms charac-
terized by virtually mutually exclusive driver mutations in 
Janus Kinase 2 (JAK2), calreticulin (CALR), and myelopro-
liferative leukemia virus oncogene (MPL). These mutations 
lead to constitutive activation of the JAK- signal transducer 
and activator of transcription (STAT) signaling pathways 
promoting clonal myeloproliferation, production of inflam-
matory mediators, and progressive myelofibrosis.1 Chronic 
inflammation and a dysregulated immune system with im-
paired tumor surveillance are considered of importance in the 
pathogenesis and clonal evolution of MPN.2
The JAK1-2 inhibitor ruxolitinib is a potent anti- 
inflammatory agent and has shown promising results in 
the treatment of patients with MF3-5 and PV6 in regard 
to reducing splenomegaly, constitutional symptoms, and 
inflammation- mediated comorbidities. However, in the large 
majority of patients, ruxolitinib does not markedly reduce the 
JAK2V617F allele burden (%V617F).5-7
Interferon- α2 (IFNα2) has potent antiproliferative and im-
munomodulatory effects and is devoid of suspicion of leukemo-
genicity unlike most available cytoreductive agents.8 Pegylated 
forms of IFNα2 (PEG- IFNα2) allow administration once weekly 
and have proven efficacious in ET9-12 and PV9-15. Patients in 
the early phase of MF, defined by low- or intermediate- risk 
disease on the Dynamic International Prognostic Scoring 
System (DIPSS) scale,16 have also been shown to benefit from 
treatment with IFNα2.9,17,18 Of note, in a subset of patients, 
long- term treatment with IFNα2 induces deep molecular re-
mission sustained even years after cessation of therapy.9-11,13-15 
However, the use of IFNα2 is limited by toxicity with an aver-
age discontinuation rate of 10- 30%.10,12,19 Moreover, in a subset 
of MPN patients molecular responses are absent, which is in 
part attributed to additional non- driver mutations and, possibly, 
concurrent inflammation and oxidative stress.10,20
The hypothesized role of chronic inflammation in the pro-
gression of MPN and in attenuating the efficacy of IFNα2 
implies that combination therapy (CT) with IFNα2 and rux-
olitinib may be a rational strategy in patients with MPN.2,20,21 
This approach may also improve tolerability of IFNα2 by 
allowing a lower dosage and reducing the inflammation- 
mediated adverse effects. The proof- of- concept of this ther-
apeutic strategy was published recently,22 and it has been 
described as one of the most promising in MPN.23
Herein, we report an interim analysis of the ongoing 
phase II trial, the COMBI study, evaluating safety and effi-
cacy of CT with low- dose PEG- IFNα2 and ruxolitinib in 50 
patients with PV or low- /intermediate- risk MF at 12 months 
of follow- up.
2 |  PATIENTS AND METHODS
2.1 | Study design
The COMBI study (#EudraCT2013- 003295- 12) is a pro-
spective, open- label, single- arm phase II study conducted 
at three centers in Denmark from June 2014 and ongoing. 
Enrollment is completed, and a total of 51 patients have initi-
ated study medication. Treatment duration will be maximum 
24 months. The study was approved by the Danish Regional 
Science Ethics Committee and conducted in accordance with 
the principles of the Declaration of Helsinki. All patients pro-
vided written informed consent. Study medication was self- 
administered and distributed in an out- patient setting.
2.2 | Inclusion and exclusion criteria
Inclusion criteria were age ≥18 years and a diagnosis of PV 
or MF of low- or intermediate- 1 or - 2- risk on the DIPSS 
scale,16 including PMF, post- PV MF, and post- ET MF ac-
cording to, respectively, the 2008 WHO criteria24 and the 
International Working Group- Myeloproliferative Neoplasms 
Research and Treatment (IWG- MRT) criteria.25 Evidence 
of active disease was required, defined by a need for phle-
botomy, white blood cell (WBC) count ≥10 × 109/L, plate-
let count >400 × 109/L, constitutional symptoms, pruritus, 
symptomatic splenomegaly, or previous thrombosis. A minor 
albeit not absolute criterion was intolerance and/or unrespon-
siveness to previous treatment with IFNα2.
Exclusion criteria were pregnancy, allergic hypersensitivity 
to any of the study medications, Eastern Cooperative Oncology 
Group (ECOG) performance status ≥3, other active malig-
nancy within the past five years, impaired renal or hepatic 
function (serum creatinine >2 ×  the upper limit of the normal 
range (ULN), total serum bilirubin >1.5 ×  ULN, serum ala-
nine transaminase >3 ×  ULN), chronic hepatitis with decom-
pensated cirrhosis or treatment with immunosuppressive drugs 
(with the exception of corticosteroids) within the preceding 
six months, former psychiatric disease, severe neurologic dis-
ease, uncontrolled metabolic disease, severe cardiac disease 
(NYHA class 3- 4), leukopenia (WBC count <1.5 × 109/L), or 
thrombocytopenia (platelet count <100 × 109/L).
2.3 | Study endpoints
The primary endpoint was complete (CR) or partial (PR) 
remission assessed at 12 months of follow- up (the interim 
analysis) and at 24 months of follow- up (the final analysis).
Secondary endpoints included toxicity, complete hematologic 
response (CHR), complete (CMR) or partial (PMR) molecular 
remission, and responses in individual hematologic parameters, 
splenomegaly, and patient- reported outcomes (PRO).
Remission definitions in PV were in accordance with the 
European LeukemiaNet (ELN) and IWG- MRT 2013 revised 
   | 3573MIKKELSEN Et aL.
criteria.26 In MF, remission was defined by the IWG- MRT 
and ELN 2013 revised criteria.27 These remission definitions 
encompass histologic, hematologic, and clinical responses 
(Appendix S1).
CHR was defined in accordance with the criteria for pe-
ripheral blood count remission in the 2013 revised response 
criteria26,27 (Appendix S1).
Evaluation of toxicity followed the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
version 4.28 Tolerability to therapy was inversely assessed by 
discontinuation rate.
The JAK2V617F allele burden was assessed by quantita-
tive real- time polymerase chain reaction performed on DNA 
purified from peripheral blood granulocytes with the recom-
mended ELN/MPN&MPNr- EuroNet JAK2V617F assay.29 
Molecular remission definitions were in accordance with the 
ELN and IWG- MRT 2013 criteria26 (Appendix S1).
PRO endpoints are described in Appendix S2.
2.4 | Treatment
Initial therapy was PEG- IFNα2a (Pegasys®; Genentech (Roche), 
South San Francisco, CA, USA) 45 μg or PEG- IFNα2b 
(PegIntron®; Merck Sharp & Dohme, Hertfordshire, UK) 
35 μg once weekly subcutaneously and ruxolitinib (Jakavi®; 
Novartis, Basel, Switzerland) 20 mg BID orally, the ruxoli-
tinib dose being dependent on the platelet count. The doses 
and dose schedules were modified based on toxicity or lack 
of efficacy. If needed, patients were phlebotomized to reach 
the target hematocrit of <0.45 (males) or <0.42 (females). All 
patients received aspirin 75 mg daily unless contraindicated. 
Baseline investigations and initiation of CT were preceded by 
a wash- out period of seven days from discontinuation of previ-
ous MPN- directed therapy.
2.5 | Evaluations
Follow- up study visits were scheduled at baseline, 2 weeks, 
1 month, 3 months, and every 3 months thereafter until 
24 months = end of treatment. Investigations performed dur-
ing follow- up are described in Appendix S3.
2.6 | Statistical analyses
The follow- up time was 12 months. Efficacy was evaluated 
by use of a modified intention- to- treat (ITT) analysis. This 
method excluded patients who were deemed ineligible early 
after enrollment. For the calculation of median values, the 
per- protocol study population was used, excluding patients 
who at a previous time point had discontinued study medica-
tion, and patients with a missing measurement.
Efficacy was primarily assessed using descriptive statis-
tics. The Wilcoxon matched- pairs signed rank test was used for 
comparing paired quantitative variables and Fisher’s exact test 
for contingency analysis of response groups. P values <.05 de-
noted statistical significance. Analyses were performed using 
the GraphPad Prism 7.0 software (San Diego, CA, USA).
Sample size calculation: We set the expected propor-
tion of patients achieving the primary endpoint with CT to 
0.45 (estimated), the reference value to 0.27 (proportion of 
patients achieving the primary endpoint with IFNα2 mono-
therapy30), the power to 0.8 and the type I error rate to 0.05. 
Accordingly, our sample size should be 41 patients (One- 
Sample Proportion Test, One- Sample, One- Sided).31
3 |  RESULTS
Of the 51 enrolled patients who started study medication, one 
patient with CALR- mutated PMF died from transformation to 
acute myeloid leukemia (AML) after receiving the first dose 
of study medication and before reaching the 2 weeks study 
visit. This patient was included in the safety analyses but not 
in the efficacy analyses or patient demographics.
3.1 | Patient characteristics
3.1.1 | Polycythemia vera
Thirty- two patients (64%) had PV. Baseline demographics 
and disease characteristics of the patients are summarized in 
Table 1. All patients had received MPN- directed therapies 
prior to enrollment, although one patient was not in active 
treatment at the time of enrollment. One patient was enrolled 
within six weeks of diagnosis due to a heavy disease burden 
with a frequent phlebotomy requirement despite cytoreduc-
tive therapy with hydroxyurea (HU).
3.1.2 | Myelofibrosis
Of the 50 patients included in the efficacy analyses, 18 
(36%) had MF (Table 1). One patient with post- PV MF was 
MPN treatment- naïve and was enrolled shortly after the 
time of diagnosis due to inflammation- mediated comorbid-
ity (polymyalgia rheumatica) and, thus, a possible benefit 
of a CT with ruxolitinib. Six patients were non- mutated in 
JAK2 of which four had mutations in CALR, and two pa-
tients had neither mutations in JAK2, CALR, or MPL (triple- 
negative MF).
3.2 | Complete and partial remission
3.2.1 | Polycythemia vera
CR was not achieved in any of the 32 patients. PR was 
achieved in three patients (9%; Appendix S4a); 22 patients 
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(69%) had no response (Figure 1A). Six patients discontinued 
study medication before 12 months of follow- up and were not 
evaluated for remission in the absence of a control bone mar-
row biopsy. In one patient, an assessment of remission was 
not made since a control bone marrow biopsy was not per-
formed (investigator’s decision out of consideration for the 
patient). No patients had progressive disease. However, five 
of the non- responding patients had marrow morphology con-
sistent with post- PV MF at 12 months of follow- up (in two 
patients unchanged from baseline; in three patients represent-
ing progression from a marrow morphology consistent with 
PV at baseline), but did not fulfill the additional criteria for 
a diagnosis of post- PV MF either at baseline or at 12 months 
of follow- up (Appendix S4a). Three of the non- responding 
patients fulfilled the criteria for histologic remission, but did 
not fulfill one or more of the other remission criteria.
Two of the three patients who achieved PR had non- 
palpable spleens at baseline. In one patient achieving PR, 
baseline palpable splenomegaly was present at 5 cm, below 
the left costal margin (LCM).
3.2.2 | Myelofibrosis
CR was achieved in 3 of the 18 patients (17%; PMF, n = 1; 
post- PV MF, n = 1; post- ET MF, n = 1), and PR was 
achieved in four patients (22%; PMF, n = 3; post- PV MF, 
n = 1; Figure 1A; Appendix S4b). Six patients (33%) had sta-
ble disease, and one patient (6%) with PMF had progressive 
T A B L E  1  Baseline demographic and clinical characteristics
Parameter
Diagnosis
Polycythemia 
vera Myelofibrosis
Number of patients, n (%) 32 (64) 18 (36)
PMF 13 (72)
Post- PV MF 4 (22)
Post- ET MF 1 (6)
Risk category on the DIPSS scale, n (%)
Low n/a 7 (39)
Intermediate- 1 n/a 11 (61)
Intermediate- 2 n/a 0
Years of age, median 
(range)
57 (36- 78) 59 (39- 72)
Gender, male/female, n 
(%)
19/13 (59/41) 10/8 (56/44)
Years from diagnosis to 
inclusion, median (range)
7.0 (0.1- 24.3) 6.0 (0.1- 17.2)
JAK2V617F mutation 
positive, n (%)
32 (100) 12 (67)
%JAK2V617F at baseline, 
median (range)
47 (1.8- 97) 45 (0.1- 97)
Previously treated with 
IFNα2, n (%)
30 (94) 17 (94)
Intolerant to IFNα2 
monotherapy
19 (59) 11 (61)
Refractory to IFNα2 
monotherapy
7 (22) 4 (22)
A combination of the 
above
4 (13) 2 (11)
Latest MPN therapy prior to enrollmenta, n (%)
IFNα2 13 (41) 7 (39)
Hydroxyurea 9 (28) 2 (11)
Anagrelide 2 (6) 3 (17)
Ruxolitinib 0 1 (5)
Combination therapy 
(≥2 of the agents 
above) including 
IFNα2
7 (22) 3 (17)b
No medical treatment 1 (3) 2 (11)c
Hematologic parameters at baseline, median (range)
Hematocrit, vol. fr. 0.43 (0.35- 0.48) 0.40 (0.31- 0.46)
WBC count, x109/L 8.8 (3.3- 40.1) 7.8 (5.0- 15.7)
Platelet count, x109/L 401 (69- 1010) 419 (143- 938)
Ultrasonographic spleen 
size (longest diameter in 
cm) at baseline, median 
(range)
13.8 (9.5- 30)d 14.0 (8- 29)
(Continues)
Parameter
Diagnosis
Polycythemia 
vera Myelofibrosis
Splenomegaly at baseline, n (%)
By ultrasonographye 19 (59) 11 (61)
By palpation 6 (19) 3 (17)
Size of splenomegaly at baseline, median (range)
By ultrasonography, 
longest diameter in cm
14.5 (13.1- 30) 17.9 (13.5- 29)
By palpation, cm below 
the LCM
7.5 (2- 21) 18 (18)
DIPSS, Dynamic International Prognostic Scoring System; JAK, Janus kinase; 
IFN, interferon; MPN, myeloproliferative neoplasm; WBC, white blood cell; 
LCM, left costal margin; n/a, not applicable.
aDuring the preceding six months.
bIncluding one MF patient treated with combination therapy of anagrelide and 
hydroxyurea.
cIncluding one MF patient without medical treatment for one year (previously 
treated with IFNα2).
dOne PV patient splenectomized. In another PV patient, no baseline imaging of 
spleen available (not performed). These two patients not included.
eDefined by longest diameter >13 cm.
T A B L E  1  (Continued)
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disease (a significant increase in spleen volume from base-
line; Appendix S4b). Three PMF patients, of whom two 
harbored CALR mutations, discontinued study medication 
before 12 months of follow- up and were not evaluated for 
remission. In one patient, also CALR- mutated, an assessment 
of remission was not made, since a control marrow biopsy 
was not performed due to risk of bleeding under antiplate-
let therapy. The remaining patient of the four CALR- mutated 
patients had stable disease. The two triple- negative patients 
achieved CR and maintained stable disease, respectively.
All seven patients who achieved remission had non- 
palpable spleens at baseline.
3.3 | Complete hematologic response
3.3.1 | Polycythemia vera
Five patients were in CHR at baseline (Figure 1B). Counting 
only patients not in CHR at baseline, CHR was achieved 
at some point in 22 out of 27 patients (81%) and sustained 
≥3 months including at 12 months of follow- up in 12 pa-
tients (44%) with a median time to response of 1 month 
(range, 0.5- 6 months).
All five patients in CHR at baseline had disease- related 
symptoms at baseline and, thus, evidence of active disease.
Responses in individual hematologic parameters, spleno-
megaly, and PROs are presented in Appendix S5a.
3.3.2 | Myelofibrosis
Six patients were in CHR at baseline (Figure 1C). Counting 
only patients not in CHR at baseline, CHR was achieved at some 
point in 11 out of 12 patients (92%) and sustained ≥3 months 
including at 12 months of follow- up in 7 patients (58%; PMF, 
n = 4; post- PV MF, n = 2; post- ET MF, n = 1) with a median 
time to response of 3 months (range, 0.5- 9 months).
All six patients in CHR at baseline had constitutional 
symptoms at baseline.
Response in PROs is presented in Appendix S5b.
3.4 | Molecular response
3.4.1 | Polycythemia vera
A decline in %V617F was observed in 28 patients (88%) dur-
ing follow- up, with no evidence of a plateau in half of these 
F I G U R E  1  (A) The distribution of patients in response categories as defined by the ELN and IWG- MRT 2013 revised response criteria 
(including histologic, hematologic, and clinical response) at 12 months of follow- up. PV patients, n = 32; MF patients, n = 18. (B, C) The fraction 
of patients in complete hematologic response (defined in Appendix S1) at baseline (0 months), 2 weeks (0.5 months), 1 month, 3 months, 6 months, 
9 months, and 12 months
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patients (Figure 2A; Appendix S6a). The median %V617F 
decreased significantly from 47% (range, 1.8- 97%) at base-
line to 23.5% (range, 0.73- 89%) at 12 months (P < .0001; 
Figure 2B). No patients achieved CMR; PMR was achieved 
in six patients (19%) by 3 months (n = 2), 6 months (n = 1), 
and 12 months (n = 3), respectively.
The three patients in PR at 12 months were among the 
six patients achieving PMR (50% PR in molecular respond-
ers versus 0% PR in molecular non- responders; P = .004). 
The median baseline %V617F was not significantly different 
between the molecular responders (60%, range, 24- 84%) and 
the molecular non- responders with %V617F ≥20 (n = 18; 
67%, range, 26- 97%; P = .387).
3.4.2 | Myelofibrosis
In 10 of the 12 JAK2- mutated patients (83%), a decline in 
%V617F was observed during follow- up with no evidence of 
a plateau in half of these patients (Figure 3A; Appendix S6b). 
The median %V617F decreased significantly from 45% (range, 
0.1- 97%) at baseline to 18% (range, 0.08- 95%) at 12 months 
(P < .0001; Figure 3B). No patients achieved CMR, although 
F I G U R E  2  (A) Dynamics of the JAK2V617F allele burden (% JAK2V617F) in individual PV patients. (B) Median % JAK2V617F including 
range and 25 and 75 percentiles at baseline (0 months), 3 months, 6 months, and 12 months. One missing value in one patient at 6 months
F I G U R E  3  (A) Dynamics of the mutant allele burden in individual MF patients. (black dot) depicting mutant allele burden in JAK2- mutated 
patients; (grey triangle) depicting mutant allele burden in CALR- mutated patients, excluding one patient with discontinuation of study therapy after 
1 month of follow- up. (B) Median JAK2V617F allele burden (% JAK2V617F) including range and 25 and 75 percentiles at baseline (0 months), 
3 months, 6 months, and 12 months
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one PMF patient with a baseline %V617F of 0.1% had no de-
tectable mutant clone at 6 months but became detectable again 
at 12 months at 0.08%. PMR was achieved in two patients 
(17%) with PMF and post- PV MF, respectively, by 6 months 
with a further decline in %V617F at 12 months. One additional 
patient achieved non- sustained PMR at 6 months; at 12 months 
of follow- up, %V617F had increased to baseline level follow-
ing a pause of PEG- IFNα2 for 3 months due to headache.
Both patients achieving sustained PMR were in PR at 
12 months (100% PR in molecular responders versus 40% 
CR/PR in molecular non- responders; P = .125).
The dynamics of the mutant allele burden in the CALR- 
mutated patients are depicted in Figure 3A and listed in 
Appendix S6b.
3.5 | Toxicity
Fifty- one patients (PV, n = 32; MF, n = 19) were included 
in the safety analyses. Hematologic toxicities were the most 
common adverse events (AE) and were managed by dose re-
duction or pausing of study medication. Anemia (PV, 56%; 
MF, 74%), leukopenia (PV, 50%; MF, 26%), and neutropenia 
(PV, 0%; MF, 16%) were in all patients of grade 1- 2 while 
thrombocytopenia (PV, 28%; MF, 32%) of grade ≥3 was re-
ported in one PV patient (platelet count 13 × 109/L).
The most common non- hematologic AEs, regardless 
of causality, were arthralgia and/or myalgia (n = 40, in 
24 patients), symptoms related to PEG- IFNα2 injection 
(flu- like symptoms, injection site reactions; n = 36, in 
24 patients), and gastrointestinal symptoms (nausea, ab-
dominal pain, dyspepsia, diarrhea; n = 31, in 27 patients; 
Appendix S7).
Thirty- seven serious AEs (SAE) were recorded in 23 pa-
tients (45%; Table 2). All SAEs, except for conversion to AML 
resulting in death, were defined so by consequent hospital ad-
mission. Four SAEs; angina pectoris, herpes zoster (n = 2), and 
anemia/thrombocytopenia, were considered causally related to 
study therapy, with the angina pectoris patient and one patient 
with herpes zoster leading to treatment discontinuation. One 
thromboembolic event (ischemic stroke) was recorded in a PMF 
patient during the follow- up period.
Twenty- six PV patients (81%) and 15 MF patients (79%) 
remained on study medication at 12 months of follow- up 
(Figure 4).
Serious adverse event Polycythemia vera, n Myelofibrosis, n
Fever 1 (+vomiting) 5a (+cystitis in 1 case)
Pneumonia 4 2
Bacterial infection, not otherwise specified 1 2b (+anemia)
Melena 3a
Extremity pain 1 1
Angina pectoris 1c,1
Arterial hypertension 2b
Herpes zoster 2c
Conversion to AML 1 (fatal outcome)
Ischemic stroke 1
Lipotymia 1
Diverticulitis with sepsis 1
Dehydratio 1
Phlebitis 1
Peripheral facial palsy 1
Anemia, thrombocytopenia 1c
Dyspnea 1
Influenza 1
Operative removal of bladder tumor 1
Total 19 18
Number of patients with ≥1 serious 
adverse event(s) (%)
15 (47) 8 (42)
AML, acute myeloid leukemia.
PV patients, n = 32; MF patients, n = 19.
aIn 2 patients.
bIn 1 patient.
cConsidered causally related to study therapy.
T A B L E  2  Serious adverse events
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Dose modifications and median doses of study medica-
tion are presented in Appendix S8a,b.
4 |  DISCUSSION
In this first study of CT with PEG- IFNα2 and ruxolitinib 
in patients with PV (n = 32) or low- /intermediate- risk MF 
(n = 18) - mainly patients being intolerant and/or refractory to 
IFNα2 monotherapy (94%) - remission (ELN and IWG- MRT 
2013 revised response criteria including histologic, hemato-
logic, and clinical responses26,27) was achieved at 12 months 
of follow- up in a subset of PV patients (9%, PR) and a large 
fraction of MF patients (39%, including CR in 17%) in con-
cert with a significant decline in the median %V617F. A high 
number of SAEs (n = 37, in 23 patients), but no unexpected 
toxicities, were reported, and the discontinuation rate was 
20%. One thromboembolic event was reported, and one case 
of progressive disease, both in PMF patients.
An advantage of this pioneering study was the multipara-
metric evaluation of treatment efficacy in both PV and MF 
patients. Furthermore, international consensus- based remis-
sion definitions were applied, with remission criteria not only 
encompassing improvement in or normalization of peripheral 
blood counts and spleen size, as used in multiple prior stud-
ies,9,10,13 but also of marrow morphology and disease- related 
symptoms. The 2013 revised response criteria were published 
after the preparation of the study protocol; however, for the 
evaluation of efficacy in this interim analysis, we chose to 
adopt these. The revised response criteria correlate better 
with measures of benefit for the patients than the 2009 crite-
ria originally intended as the primary endpoint of this study. 
However, it was necessary to modify the 2013 criteria by not 
including an assessment of palpable hepatomegaly, and in 
MF by confirming changes in spleen size by ultrasonogra-
phy instead of MRI/CT since these investigations were not 
performed.
Our study has other limitations to consider. Firstly, the 
cohort size of MF patients, in particular, is relatively small, 
and the follow- up period is short, which hinders the detection 
of rare or long- term toxicities, as well as the evaluation of 
depth and long- term sustainability of responses. Secondly, 
F I G U R E  4  Patient distribution and representation of patient discontinuations of study medication. () the (serious) adverse event(s) leading to 
discontinuation of study therapy, *serious adverse event. d/c, discontinuation of study medication
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the initial dosage of ruxolitinib of 20 mg BID differs from 
the recommended 10 mg BID for PV patients, because the 
ruxolitinib dose- finding study32 had not been published by 
the time the protocol for this study was prepared. However, 
in the majority of patients, doses were decreased according 
to peripheral blood counts. Thirdly, we applied a modified 
ITT analysis instead of a true ITT. Separating the modi-
fied ITT analysis from a true ITT analysis is the exclusion 
of screen failure patients deemed ineligible due to failure to 
meet the in- /exclusion criteria (patients who never received 
study medication), and the exclusion of the one MF patient 
who died from transformation to AML within two weeks of 
study start (erroneous implementation of eligibility criteria). 
This patient was, however, included in the safety analyses. 
In terms of presenting clinically meaningful analyses of the 
efficacy and safety of the study therapy giving maximum in-
formation to clinicians, we consider the use of the modified 
ITT analysis to be a rational approach without risking bias.33
Fourthly, based on the median values for baseline periph-
eral blood counts (Table 1), one could argue that the patient 
population, seemingly having a low burden of disease, was not 
representative. However, these median baseline values were 
influenced by a high number of prior phlebotomies and a rel-
atively short preceding wash- out period of seven days. Eleven 
patients in total (22%; PV, n = 5; MF, n = 6) were in CHR 
(based solely on peripheral blood counts) at baseline, all of them 
having disease- related/constitutional symptoms at baseline.
These limitations notwithstanding, our preliminary results 
are remarkable since few prior studies in MPN have shown 
remission rates (by the revised definitions) of this amplitude 
at one year of follow- up.
In a prospective study of IFNα2 monotherapy in pa-
tients with PMF, post- PV MF, or post- ET MF of low- or 
intermediate- 1- risk disease, CR and PR (2013 IWG- MRT 
and ELN criteria) were achieved in 7% (2/30) and 30% (9/30) 
of patients, respectively, with a median therapy duration in 
the cohort of 5.6 years.18
In the context of the encouraging results of this CT, it 
is relevant to consider, if similar results might be obtained 
with ruxolitinib alone. Monotherapy with ruxolitinib in 
phlebotomy- dependent PV patients with splenomegaly who 
were resistant or intolerant to HU was in a phase III study 
associated with CHR in 24% of patients after eight months.6 
In our study, sustained CHR was achieved in 44% of PV 
patients and 58% of MF patients, who were not in CHR at 
baseline, by a median follow- up time of 1 month (range, 
0.5- 6 months) and 3 months (range, 0.5- 9 months), respec-
tively. Furthermore, ruxolitinib has no or minor impact on the 
malignant clone but primarily on the inflammatory process 
associated with MPNs. Thus, we suggest that CT targeting 
both the malignant clone (IFNα2) and the inflammatory state 
(ruxolitinib) may be superior to monotherapy with ruxolitinib 
as described in most recent reviews.2,21,23
HU is the most widely used cytoreductive agent interna-
tionally and is efficient in reducing elevated peripheral blood 
counts and preventing thrombosis. However, studies of the 
effect of HU on the JAK2V617F allele burden have shown 
divergent results.34 In this regard, the direct prognostic rel-
evance of a reduction in the JAK2V617F allele burden is 
not fully elucidated, however, a higher allele burden seems 
to be associated with a more advanced disease stage and 
more symptoms, a higher risk of disease evolution, and an 
increased risk of thrombosis.35,36 Thus, the reduction in allele 
burden is considered a clinically relevant endpoint and a valid 
surrogate marker for treatment efficacy.
We found that remission rates were higher among patients 
in PMR than among patients not in PMR (significant only for 
PV patients), and higher remission rates were also observed 
among patients with >50% reduction in total symptom score 
within the first 2 weeks of therapy than among patients with-
out (non- significant; Appendix S5a,b). In regard to the for-
mer, results from other studies are divergent.37,38 In addition, 
remission was achieved only in patients with baseline pal-
pable splenomegaly ≤5 cm, below the LCM, supporting the 
findings of other studies.39
A finding that must be stressed is the high number of 
SAEs. However, a large proportion of hospitalizations elic-
iting SAEs were effectuated as a precaution in the context of 
an experimental CT rather than reflecting severely affected 
patients. Accordingly, many hospitalizations were terminated 
within 24 hours. Some of these hospitalizations might have 
been explained by the initial dosage of ruxolitinib of 20 mg 
BID which we also underscore as a limitation of our study. In 
future studies of this combination therapy, the recommended 
10 mg BID for PV patients should be used initially,32 thereby 
hopefully reducing the incidence of SAE’s.
Moreover, 94% of patients were intolerant and/or re-
fractory to IFNα2 monotherapy, yet tolerability of CT was 
comparable to the one reported with low- dose PEG- IFNα2 
monotherapy in IFNα2- naïve patients.12
It is reasonable to question a possible synergistic effect of 
combining IFNα2 and ruxolitinib, when ruxolitinib by inhib-
iting JAK1 and JAK2 and, thereby, the JAK- STAT- signaling 
pathway, might actually prohibit IFNα2 signaling which is 
mediated through primarily JAK1. However, ruxolitinib has a 
short half- life of approximately 3 hours as opposed to PEG- 
IFNα2 with a prolonged half- life of several days. This leaves 
a time window of several hours daily, in which IFN signaling 
is possible.21 However, a JAK2- selective inhibitor might syner-
gize more with IFNα2 and should be explored in future studies.
In conclusion, the preliminary results from this study 
 suggest that CT with low- dose PEG- IFNα2 and ruxolitinib 
is feasible and efficacious in patients with low- /intermediate- 
risk MF and, to a lesser extent, in patients with PV, includ-
ing in patients who were unresponsive or intolerant to IFNα2 
monotherapy. These results warrant phase III studies to assess 
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the safety and efficacy of CT compared to current standard 
treatment modalities as well as a study with CT in patients 
with newly diagnosed PV or low- /intermediate- risk MF. In 
these studies, lower initial dosages of ruxolitinib (10 mg BID 
for PV patients) and PEG- IFNα2a (Pegasys® 45 ug once 
weekly or every second week subcutaneously) should pref-
erentially be used in order to reduce the toxicity of this novel 
combination therapy.
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